Le Lézard

News by subject: TRI

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

8 november 2023

13:28
In honour of Diabetes Awareness Month, Novo Nordisk, JDRF, Diabetes Canada, the McEwan Stem Cell Institute, and the filmmakers behind The Human Trial gathered a diverse and passionate audience at the National Arts Centre last night, Tuesday, November...

13:18
Aitia, the leader in the application of Causal AI and Digital Twins to discover and develop new drugs, announced today that data from its neurodegenerative disorders Digital Twins, including Alzheimer's Disease (AD) and Parkinson Disease (PD), will...

13:00
Stimvia, a company specializing in the use of neuromodulation for the treatment of chronic diseases, successfully completed recruitment for a pilot study focused on the treatment of Parkinson's disease (PD) and essential tremor (ET). Patients will be...

12:22
The U.S. Food and Drug Administration (FDA) approved Eli Lilly and Company's Zepboundtm (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP (glucose-dependent...

11:21
Sfunga Therapeutics ("Sfunga"), a biotechnology company, and Deerfield Management Company ("Deerfield"), a healthcare investment firm, today announced the publication of data on a novel antifungal molecule AM2-19 in the scientific journal Nature.[1]...

09:33
AG-73305 was found to be safe and tolerable with no severe adverse effects (SAEs) after a single intravitreal injection of doses of 0.5, 1, 2, and 4 mg in DME patients.Data combining all 4 cohorts showed mean improvement in Best Corrected Visual...

09:01
Janssen Pharmaceuticals, Inc., a Johnson & Johnson company, today announced new data from the CorEvitas Psoriatic...

08:31
Recurring influenza epidemics, such as the one during World War I, the Middle East respiratory syndrome coronavirus (MERS-CoV) outbreak in the 2010s, and the COVID-19 pandemic in recent years have made it evident that contagious viral respiratory...

08:30
Arthrosi Therapeutics, Inc., a clinical-stage biotechnology company developing treatments for gout that dissolve uric acid crystals and prevent joint damage, today announced new clinical data from its phase 2 AR882-203 study in patients with...

08:10
Recor Medical, Inc. ("Recor") and its parent company, Otsuka Medical Devices Co., Ltd. ("Otsuka Medical Devices") today announced the U.S. Food and Drug Administration (FDA) has approved Recor's Paradisetm Ultrasound Renal Denervation (RDN) system...

08:10
Foresee Pharmaceuticals (TPEx: 6576), ("Foresee") announced today preclinical data in the European Heart Journal, demonstrating that activation of Aldehyde Dehydrogenase 2 (ALDH2) with Foresee's oral ALDH2 activator AD-9308, significantly ameliorates...

08:00
Alimentiv Inc., AcelaBio Inc., and PharmaNest Inc. are pleased to announce their collaborative effort aimed at revolutionizing precision medicine and artificial intelligence (AI)-enabled digital pathology solutions for metabolic...

07:00
Today, Acorai, a start-up medical device manufacturer from Sweden, announces selection for a ?2.3m grant with a follow-on ?10m investment offer from the European Innovation Council (EIC). Only a handful of companies who apply for the EIC accelerator...

06:45
Mallinckrodt plc , a global specialty pharmaceutical company, today announced the...

06:30
BIOLASE, Inc., the global leader in dental lasers, today announced groundbreaking findings from a 12-month follow-up to a clinical trial performed at The McGuire Institutetm. The findings will be published in the November 2023 issue of the Journal of...

05:00
Genetic information collected from seemingly healthy tissue near lung tumors may be a better predictor of whether cancer will come back after treatment than analysis of the tumors themselves, according to new research led by NYU Langone Health and...

03:00
Alimentiv Inc., AcelaBio Inc., and PharmaNest Inc. are pleased to announce their collaborative effort aimed at revolutionizing precision medicine and artificial intelligence (AI)-enabled digital pathology solutions for metabolic...


7 november 2023

16:05
Amgen today announced results from the global Phase 4 FOREMOST study evaluating Otezla® (apremilast) in patients with early oligoarticular psoriatic arthritis. FOREMOST is the first placebo-controlled study designed to specifically assess people...

16:05
AcelRx Pharmaceuticals, Inc. , (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically...

16:05
Tyra Biosciences, Inc. , a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in...

16:01
Compelling efficacy signal in favor of larsucosterol in the key secondary endpoint of mortality at 90 days.  Clinically relevant reduction in 90-day mortality of 41% for 30 mg dose and 35% for 90 mg dose compared with standard of care (SOC)...

16:00
Amgen today announced new data from its Phase 2 study evaluating dazodalibep, an investigational medicine, for the treatment of Sjögren's. These results will be featured in...

12:01
ORSERDU is the first treatment specifically approved for patients with ER+, HER2- advanced or metastatic breast cancer tumors that harbor ESR1 mutations, representing the first innovation in endocrine therapy in nearly 20 years.ESR1 mutations are...

10:45
A new clinical trial is currently recruiting men struggling with a painful, but not uncommon, condition: chronic scrotal pain. The Phase II study is testing an important new therapeutic approach to treat this condition at our centre in Vancouver and...

10:14
Immunovia , the diagnostics company focused on early detection of pancreatic cancer, today announced the successful completion of the discovery phase for the Company's next-generation test.  The discovery study, which marks a key milestone in the...

10:01
The Janssen Pharmaceutical...

10:00
The American College of Rheumatology Convergence 2023 meeting will be held in San Diego, CA from November 10-15, 2023. Innovative studies and research funded or supported by the Lupus Foundation of America (LFA) will be presented including...

09:00
AppliedVR, an immersive therapeutics (ITx) pioneer advancing a novel, virtual reality-based approach to medicine, today announced results from a large randomized controlled trial (RCT), evaluating virtual reality (VR) therapy for treating chronic low...

09:00
Veradermics Inc., a clinical-stage medical dermatology company with a pipeline of first-in-class product candidates targeting highly prevalent immunologic and dermatologic conditions, today announced it has commenced dosing in a First-in-Human...

08:58
Clarity Pharmaceuticals ("Clarity"), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce that 50 patients have...

08:47
A 'hands-on' therapy that can feel like a deep massage has replaced major surgeries in two fields of medicine: female infertility and serious digestive problems per researchers at Clear Passage® Therapies. Following decades of research, studies show...

08:36
Amsety, a liver health solutions start-up announced the release of its new artificial intelligence-driven Amsety Clinical Recruitment Engine ("ACRE"). ACRE combines decisional AI and messaging tools with a proprietary, self-selected database of over...

08:35
SciTech Development, LLC, today announced the finalization of agreements with Columbia University, the University of Southern California Keck Medicine, and the University of Pittsburgh Medical Center to host clinical trials for SciTech's new drug ?...

08:30
PreciseDx®, a leading innovator in oncology diagnostics, leveraging Artificial Intelligence (AI) for revolutionary, morphology-driven, disease analysis, today announced that its analytical validation study for its PreciseBreasttm assessment has been...

08:30
Discover an innovative webinar delving into how ICON ? a healthcare...

08:30
Novo Nordisk today announced the upcoming presentation of new data that helps reinforce the company's commitment to driving change and addressing unmet needs of people living with cardiometabolic diseases. Results will be presented at the upcoming...

08:15
Myrtelle Inc. ("Myrtelle" or the "Company"), a clinical-stage gene therapy company focused on developing transformative treatments for neurodegenerative diseases, today announced that Christopher Janson, M.D., Principal Investigator on Myrtelle's...

08:03
The dropout rate for clinical trials...

08:00
Johnson & Johnson MedTech* today announced plans to submit the OTTAVA robotic surgical system for an investigational device exemption (IDE) application to the U.S. Food & Drug Administration...

07:45
Jazz Pharmaceuticals plc  and The University of Texas MD Anderson Cancer Center today announced a five-year strategic research collaboration agreement to evaluate zanidatamab, Jazz's investigational HER2-targeted bispecific antibody, in multiple...

07:00
Preliminary data for FPI-2265 (225Ac-PSMA I&T) in approximately 20 to 30 patients on track for Q1 2024 Data from Cohort 2 of the FPI-1434 Phase 1 study anticipated around year-end 2023 FPI-2068, a bispecific IgG-based targeted alpha therapy for...

07:00
EOM Pharmaceutical Holdings, Inc.  ("EOM") today provides an update on its clinical program for its lead drug candidate EOM613. EOM613 is a peptide-nucleic acid-based broad spectrum immune regulating agent that acts on both key pro-inflammatory and...

07:00
Akeso (9926.HK) announced positive results from an interim analysis of AK104-302 study, a randomized, double-blind, multicenter, phase III clinical study evaluating PD-1/CTLA-4 bispecific antibody, cadonilimab (???®) in combination with capecitabine...

06:00
Strong balance sheet of $511.1 million of cash, cash equivalents and marketable securities as of September 30, 2023, supplemented by $134.7 million estimated net proceeds from subsequent follow-on financing and $10.0 million receivable from GSK...

05:11
QNTM Labs is pleased to announce the significant expansion to its existing headquarters. The company's new 1,000 sq/m space builds upon the original 600 sq/m of operations and has received additional EU-GMP certifications. This expansion serves as a...

01:14
BioRay Pharmaceutical Co., Ltd. (hereinafter referred to as BioRay) announced that the first patient has been dosed in the Phase I Clinical trial of BRY812, a third-generation antibody-drug conjugate (ADC) targeting LIV-1 for the treatment of...


6 november 2023

23:31
Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter) announced that two major clinical updates of its CSF-1R inhibitor pimicotinib?ABSK021?were presented at the 2023 Connective Tissue Oncology Society Annual Meeting, which is held in...

20:00
Calliditas Therapeutics AB ("Calliditas"), today announced data presentations highlighting additional analyses from the Phase 3 NefIgArd study with Nefecon in adults with primary IgA nephropathy (IgAN), as well as pre-clinical data on the treatment...

19:00
Daewoong Pharmaceutical (CEOs Seng-Ho Jeon and Chang-Jae...

17:30
Rakuten Medical, Inc., a global biotechnology company developing and commercializing precision,...

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15